Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Stable formulations of a hyaluronan-degrading enzyme

A technology of hyaluronan and hyaluronidase is applied in the field of stable preparations of hyaluronan degrading enzymes, and can solve the problems of hypoglycemia, prolonged action time and the like

Inactive Publication Date: 2014-08-06
HALOZYME
View PDF152 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Also, the doses that must be administered result in prolonged action, which can cause hypoglycemia and, in many cases, obesity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stable formulations of a hyaluronan-degrading enzyme
  • Stable formulations of a hyaluronan-degrading enzyme
  • Stable formulations of a hyaluronan-degrading enzyme

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0701] Preparation of Insulin and Insulin Analog Stocks

[0702] A. Regular insulin

[0703] For regular insulin, weigh the powder (Organon Insulin API, Recombinant Human Insulin SIHR143) and mix it with an appropriate amount of water until the solution contains approximately 10-25 mg / mL of insulin. 1 M HCl was added to the turbid mixture to a final concentration of HCl of 20 mM. The solution was mixed gently with a stir bar until the insulin was completely dissolved, and 250 mM Tris, pH 10.7 (Trizma, cat# T6066, Sigma) was added to a final Tris concentration of 20 mM. Insulins were formulated as described in each of the individual examples below using 1 M NaOH to adjust the pH followed by the addition of water. This insulin contains approximately 13 μg / mL zinc.

[0704] B. Insulin analogues

[0705] For insulin analogs (insulin aspart or insulin lispro), combine 12 vials (10 mL each) of commercially available product (insulin lispro: Eli Lilly (Insulin lispro) 100U / mL, ...

Embodiment 2

[0707] Determination of hyaluronidase activity of rHuPH20

[0708] The hyaluronidase activity of rHuPH20 (obtained by expression and secretion of a nucleic acid encoding amino acids 36-482 of SEQ ID NO: 1 in CHO cells) was determined using a nephelometric assay. In the first 2 assays (A and B), the hyaluronidase activity of rHuPH20 was measured by incubating soluble rHuPH20 with sodium hyaluronate (hyaluronic acid), followed by precipitation of undigested by addition of acidified serum albumin of sodium hyaluronate. In the third assay (C), rHuPH20 hyaluronidase activity was measured based on the formation of an insoluble precipitate when hyaluronic acid (HA) was combined with cetylpyridinium chloride (CPC). In all assays containing 600 U / mL rHuPH20 (5 μg / mL), the acceptance criterion was an enzyme activity above 375 U / mL.

[0709] A. Microturbidimetry

[0710] In this assay, the hyaluronidase activity of rHuPH20 is measured by incubating soluble rHuPH20 with sodium hyaluron...

Embodiment 3

[0728] RP-HPLC

[0729] In this example, reverse phase-HPLC (RP-HPLC) was used to determine the apparent solubility of insulin and insulin analogs and the percent purity of rHuPH20. Apparent solubility was measured as percent insulin recovery relative to the initial formulation / condition.

[0730] reference standard

[0731] For regular insulin, use (regular insulin, 100U) as a standard. For insulin lispro, reconstitute 1 vial of USP insulin lispro with 1.72 mL of 0.01N HCl to obtain a 3.5 mg / mL USP insulin lispro (100 U / mL) reference standard. For insulin aspart, reconstitute 1 vial of EP insulin aspart with 1.00 mL of 0.01N HCl to obtain a 3.89 mg / mL EP insulin aspart reference standard. For rHuPH20, use 3 reference standards, each containing a 50 μg / mL rHuPH20 sample (Lot #HUB0701EB ) produced 2.5 μg / mL, 5.0 μg / mL or 7.5 μg / mL rHuPH20.

[0732] Preservative Standards

[0733] Three preservative reference standards were used, each containing 0.05% m-cresol / phenol, 0....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

Provided are compositions that are stable formulations of a hyaluronan-degrading enzyme or are stable co-formulations of a fast-acting insulin and a hyaluronan degrading enzyme, including a recombinant human PH20 (rHuPH20).

Description

[0001] related application [0002] This application claims priority to US Provisional Application Serial No. 61 / 520,962, filed June 17, 2011, entitled "STABLECO-COFORMULATIONS OF A HYALURONAN-DEGRADING ENZYMEAND AN INSULIN." [0003] This application is related to US Application Serial No. 13 / 507,263, filed on the same date herewith, entitled "STABLE FORMULATIONS OFA HYALURONAN-DEGRADING ENZYME," which claims priority to US Provisional Application Serial No. 61 / 520,962. This application is also related to US Application Serial No. 13 / 507,262, filed on the same date herein, and entitled STABLE FORMULATIONS OF AHYALURONAN-DEGRADING ENZYME, which claims priority to US Provisional Application Serial No. 61 / 520,962. The subject matter of the related application indicated above is incorporated by reference in its entirety. [0004] This application is also related to U.S. Provisional Application Nos. 61 / 520,940, filed June 17, 2011, U.S. Provisional Application Nos. 61 / 628,389, file...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/28A61K38/47A61P5/50A61P3/10
CPCA61K47/183A61K38/28A61K38/47A61K2300/00A61K9/0019A61K47/20A61P43/00A61P5/50A61P3/10A61K47/36A61K2121/00
Inventor T-H·扬M·J·拉巴尔D·E·沃恩C·L·卡斯特F·尼科尔D·金
Owner HALOZYME
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products